Plain-English translation of NCT06974786 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a newer medication called —which works by activating your own immune cells to fight cancer—might work as well as or better than the traditional stem cell transplant approach for newly diagnosed multiple myeloma. All participants will first receive standard initial chemotherapy, and then be randomly assigned to either continue with plus another medication, or to have a stem cell transplant followed by maintenance therapy. The study will monitor how well each approach controls the cancer over time.
Multiple myeloma is a serious blood cancer, and while stem cell transplants have been the standard follow-up treatment for many years, newer immunotherapy medications are emerging as potentially promising alternatives. This trial wants to find out if the newer immune-activating approach might offer patients similar or better results with possibly fewer serious side effects.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups. One group will receive the new medication by injection, starting with a gradual dose increase and then regular weekly or bi-weekly visits, along with another medication given monthly. The other group will undergo a stem cell transplant procedure followed by monthly maintenance medication. Both groups will have regular blood tests and clinic visits to monitor how well the treatment is working and check for side effects. The treatment phase lasts about one to two years, and if your cancer shows no detectable signs after that, you may stop treatment and be monitored for recurrence.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States